Who are pentoxifylline (PTX)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pentoxifylline sustained-release tablets.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pentoxifylline-ptx.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

pentoxifylline (PTX) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

pentoxifylline (PTX) (pentoxifylline (PTX)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Methylxanthine derivative; hemorheological agent. Area: Cardiovascular; Hematology.

phase 3 Methylxanthine derivative; hemorheological agent Phosphodiesterase (non-selective); adenosine receptors Cardiovascular; Hematology Small molecule Live · refreshed every 30 min

Target snapshot

pentoxifylline (PTX) (pentoxifylline (PTX)) — Case Western Reserve University. Pentoxifylline improves blood flow and reduces blood viscosity by increasing red blood cell flexibility and decreasing platelet aggregation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
pentoxifylline (PTX) TARGET	pentoxifylline (PTX)	Case Western Reserve University	phase 3	Methylxanthine derivative; hemorheological agent	Phosphodiesterase (non-selective); adenosine receptors
Pentoxifylline sustained-release tablets	Pentoxifylline sustained-release tablets	Beijing Tiantan Hospital	marketed	Methylxanthine derivative; phosphodiesterase inhibitor	Phosphodiesterase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Methylxanthine derivative; hemorheological agent class)

Case Western Reserve University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). pentoxifylline (PTX) — Competitive Intelligence Brief. https://druglandscape.com/ci/pentoxifylline-ptx. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing